---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095766"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:46:01.161662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q2 net loss $18.8M; $220.4M cash; ACR-368 Phase 2 shows 50% ORR

## Summary
- Net loss of $18.8M vs $13.9M YoY; R&D expenses $15.0M, G&A $6.4M.
- Cash, equivalents and marketable securities $220.4M expected to fund into H2 2026.
- ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive gynecological cancer patients.
- ACR-2316 WEE1/PKMYT1 inhibitor Phase 1 on track to start 4Q 2024.
- Raised $130M in oversubscribed private placement financing.

## SEC filing metadata
- accession: 0000950170-24-095766
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/0000950170-24-095766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024095766/acrv-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095766
- JSON: https://secwatch.observer/filing/0000950170-24-095766.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.